96 For many women, cervical cancer screening remains an uncomfortable or inconvenient experience that is often delayed or avoided. New guidance, published in CA, in suggests that allowing people to collect their own vaginal samples for HPV testing could remove long standing barriers and help prevent more cases of a disease that is largely avoidable. The updated recommendations reflect growing evidence that self collected vaginal specimens can be an effective way to detect high risk human papillomavirus, the virus responsible for most cervical cancers. HPV testing is already central to modern screening programmes, but until recently it usually required a clinician performed examination. Under the revised guidance, self collection is now considered an acceptable option for people aged 25–65 who are at average risk of cervical cancer. Clinician collected samples remain the preferred approach, but self testing offers an alternative for those who struggle to attend appointments or find pelvic examinations distressing. The change follows regulatory approval of specific HPV tests that work reliably with self collected samples. Research reviewed for the update shows that self collected samples analysed using modern laboratory methods perform almost as well as samples taken by clinicians. The tests are particularly effective at ruling out disease when results are negative, offering reassurance that cancer or serious precancerous changes are unlikely to be present. However, the guidance also highlights important differences in follow up. When HPV is detected in a self collected sample, most people will still need a clinic visit for further assessment. This means self testing does not remove the need for health services, but it may reduce the number of initial appointments required and encourage more people to start screening. To reflect current evidence, the recommended interval after a negative self collected HPV test is three years rather than five. This shorter interval is designed to maintain safety while longer term data continue to emerge on how well self testing predicts future cancer risk. The update also revises advice on when cervical cancer screening should stop. Rates of cervical cancer remain surprisingly high among older women, often because screening ends too early or without adequate prior testing. The new guidance recommends HPV testing at both 60 and 65 years before screening is discontinued, ensuring that people leave screening with clear evidence of low risk. Experts involved in developing the guidance note that many women over 65 have incomplete screening histories, making it difficult to apply older rules that relied on records stretching back a decade. A simpler, forward looking approach may help reduce missed cancers in later life. Although the guidance is based on evidence from the United States, the implications are relevant internationally. In the UK and elsewhere, screening programmes face challenges linked to declining attendance, workforce pressures, and widening health inequalities. Self collected HPV testing could play a role in addressing these issues if carefully implemented. The authors stress that self testing is not suitable for everyone. People with weakened immune systems or a history of cervical cancer still require clinician led screening. Clear communication and robust follow up systems will be essential to ensure that positive results are acted on promptly.